Indian Immunologicals launches Measles & Rubella vaccine

New Delhi: Human Biologicals Institute (HBI), a division of Indian Immunologicals Limited (IIL) launched the Mabella (Measles and Rubella) vaccine for children.

This live attenuated MR vaccine has been developed by IIL in an exclusive partnership with Polyvac Institute, Vietnam. Through extensive human clinical trials, Mabella has been proven to be safe and effective.

Established in 1998, IIL celebrated its silver jubilee, with distinguished medical doctors from various parts of the country assembled in the serene precincts of Udhagamandalam (Ooty).

HBI was created in an era where the need for indigenous vaccines is paramount and thus has contributed to a self-reliant India – “Atmanirbhar Bharat”.

Upon request from Government of India, HBI indigenously developed India’s 1^st safe Vero-cell rabies vaccine – Abhayrab in 1998, paving way for Government of India to phase out the painful nerve tissue vaccine. Today, Abhayrab is the largest selling Anti-Rabies vaccine in the world. Millions of lives have been saved in India and across the world with HBI’s Abhayrab vaccine. Subsequently, several childhood vaccines such as DPT, Pentavalent Vaccine, TT, Hepatitis-B, MR, Td vaccines were introduced by HBI.

IIL’s journey of excellence in vaccine development reached its summit during the Covid 19 pandemic. IIL rose to the nation’s call and contributed to the manufacturing of many million doses of vaccines. This capability of IIL was much appreciated by NITI Ayog, Ministry of Health and Family Welfare and several other agencies.

Speaking on this occasion, Dr K Anand Kumar, Managing Director, Indian Immunologicals, spoke about the significant contribution made by IIL to the nation, towards disease control and access to several lifesaving vaccines in its 25 years of existence. “IIL has now emerged as one of the largest suppliers of human vaccines to the UIP, Ministry of Health and Family Welfare, Government of India, saving many precious lives. IIL also exports quality vaccines to more than 50 countries across the globe.”

During the launch of Mabella (Measles and Rubella vaccine) today, he also expressed the need for control of deadly Measles and Rubella, that claims about 1,00,000 lives of children globally. He also pointed out that the company should be known for elimination, eradication of disease than the number of doses of vaccine it sells. To this extent IIL has taken up CSR activity to make Thiruvanathapuram district rabies free in a few years.

“IIL adopts modern manufacturing practices to produce quality vaccines and has adequate infrastructure to meet the national requirements. By implementing environmentally sustainable packaging for Abhayrab®, IIL saved 160 tons of plastic per annum”, added Dr Priyabrata Pattnaik, Dy. MD, IIL.